References
- Pabst T, Mueller BU. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res 2009; 15: 5303–5307.
- Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Reviews 2004; 18: 115–136.
- Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New Eng J Med 2008; 358: 1909–1918.
- Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytoge netic abnormalities and FLT3 internal duplication. Blood 2009; 113: 5090–5093.
- Zhang DE, Zhang P, Wang ND, et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein adeficient mice. Proc Natl Acad Sci USA 1997; 94: 569–574.
- Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nature Genetics 2001; 27: 263–270.
- Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003; 4: 31–40.
- Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutation in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624–633.
- Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005; 11: 1372–1379.
- Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 2011; 96: 384–392.
- Schwarz JM, Cooper DN, Schuelke M, et al. MutationTaster2: mutation prediction for the deep-sequencing age. Nature Meth 2014; 11: 361–362.
- McGuffin LJ. Intrinsic disorder prediction from the analysis of multiple protein fold recognition models. Bioinformatics 2008; 24: 1789–1804
- Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. Proteins 2006; 62: 1125–1132.
- Asou H, Gombart AF, Takeuchi S, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 2003; 36: 167–174.
- Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99: 1332–1340.
- Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a sub-group of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009;113: 3088–3091.
- Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. New Eng J Med 2004; 351: 2403–2407.
- Renneville A, Mialou V, Philippe N, et al. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 2009; 23: 804–806.